Analyzing a 16S rRNA amplicon dataset breaks down into a few stages, and the choices you make early on constrain everything downstream, so it's worth being deliberate about each one rather than defaulting to whatever tutorial you find first.

**1. Raw read processing.** Your FASTQ files need quality filtering, primer trimming, and denoising/OTU-clustering before anything biological can be said about them. The two dominant modern approaches are DADA2 and Deblur — both replace older OTU-clustering (like UCLUST) with exact amplicon sequence variants (ASVs), which are reproducible across studies in a way OTUs never were. DADA2 models per-run error rates and tends to be the default choice; Deblur is faster and makes fewer distributional assumptions but is more sensitive to upstream trimming quality. Either is normally run inside QIIME2 or as a standalone R/Python package.

**2. Taxonomic assignment.** Once you have ASVs, you classify them against a reference database (SILVA, Greengenes2, or GTDB are the common ones). Database choice matters more than people expect — Greengenes2 and GTDB use different taxonomic backbones than SILVA, so switching databases mid-project will change your genus-level results.

**3. Diversity analysis.** This is usually the actual scientific question:
   - *Alpha diversity* (diversity within a sample) — richness (how many taxa), evenness, and various composite indices (Shannon, Simpson, Faith's phylogenetic diversity).
   - *Beta diversity* (diversity between samples) — Bray-Curtis, UniFrac (weighted/unweighted), used to see whether groups of samples cluster apart.

   A common mistake here is picking one alpha and one beta metric because a tutorial used them, rather than because they answer your actual question. Different metrics are sensitive to different things — some care only about presence/absence, others weight by abundance, others incorporate phylogenetic relatedness — so the "right" metric depends on the biological hypothesis, not habit.

**4. Statistical testing.** Group comparisons (Kruskal-Wallis for alpha, PERMANOVA for beta) need to account for your actual sample size and design — microbiome studies are frequently underpowered because compositional data is noisy and effect sizes are often small.

**5. Reporting.** Whatever metrics you land on, report enough of the pipeline (denoising method, reference database + version, exact metric formulas, rarefaction depth if used) that someone else could reproduce your numbers — this is a field with a real standardization problem, so specificity here matters more than in fields with more mature conventions.

Before doing any of this, the actual first question is: what's the sample type and what's the biological question? A soil microbiome study and a human gut study will often reuse the same tools, but expect very different baseline diversity, different confounders (pH, moisture, spatial structure for soil vs. diet, host genetics for gut), and potentially different reference databases. Worth nailing that down before picking a pipeline.
